Findings
bleeding
EVENTS, BLEEDING
This equivalence and noninferiority trial including 2046 patients found that short-term rivaroxaban 5 mg twice daily was noninferior to enoxaparin in terms of bleeding risk and efficacy in reducing major adverse cardiovascular events during 6 months of follow-up among patients with ACS who missed the primary reperfusion window and before selective revascularization.